Israel-based Belong.Life is the creator of the world’s largest social network for cancer patients, and has ambitions to provide a range of networks across therapy areas.
The platform may of interest for drug developers and other industry participants looking for opportunities to conduct market research or marketing efforts, or to boost clinical trial enrolment.
In this episode, The Pharma Letter discusses the potential for the platform with its chief executive, Eliran Malki, and medical director, Daniel Vorobiof.
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze